https://www.slideshare.net/DrBKAgrawal/neuroendocrine-tumors-nets?qid=c34d63bb-8495-4c65-9f4e-9348d299ed70&v=&b=&from_search=1 Neuroendocrine tumors (NETs) consists of a complex group o...
BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...
Find More
Stopping breast cancer metastasis by killing tumor cells in their sleep Oncology researchers believed that dormant breast cancer cells are not responsive to chemotherapy. But these inactive cancer cells can be active at any time and cause life-threatening metastases. Scientists at the Fred Hutchinson Cancer Rese...
Find More
A range of rare genetic disorders is pinpointed by a deep-learning algorithm. This helps doctors and researchers by analysing pictures of people’s faces. Researchers describe the technology after the diagnostic aid, a smartphone app called Face2Gene. It relies on machine-learning algorithmsand brain-like neural...
Find More
Vedanta raises USD 27 Million to move microbiome assets through the clinic Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid a phase 1/2 trial of VE416 in food allergy, a phase 2 study of VE303 in recurrent...
Find More
Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...
Find More
Lilly remunerates AC Immune USD 81 Million for preclinical Alzheimer’s drug Eli Lilly has remunerated USD 81 million upfront for the global rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The agreement provides Lilly ownership of a small molecule that has prevented tau aggregation in preclin...
Find More
If dementia genes are found, drug discovery can be accelerated in brain disorders The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer’s and other forms of dementia. But the exact genetic process that causes tau is still a mystery. Scientists of the University...
Find More
Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...
Find More
Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO. A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve ...
Find More
Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....
Find More
Intra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....
Find More
Thyroid Eye Disease (TED), also known as Grave’s Ophthalmopathy, is an autoimmune disorder in whic.....
Find More
Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification .....
Find More
Dementia is one of the major chronic and progressive syndrome caused by a number of different condit.....
Find More
BK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
